NEW YORK (GenomeWeb) – Agendia said today that it has signed an agreement with Valencia, Spain-based Imegen for the exclusive distribution of Agendia's MammaPrint and BluePrint breast cancer genomic tests in Spain and Portugal.
MammaPrint measures the expression of 70 genes and classifies patients as either high risk or low risk of recurrence over a 10-year period. BluePrint is an 80-gene assay that classifies patients as having either basal, luminal, or HER2 subtypes of breast cancer to further guide treatments.
Both tests are based on microarray technology. Agendia also separately markets the MammaPrint and BluePrint Breast Cancer Recurrence and Molecular Subtyping Kits using next-generation RNA sequencing technology.
"We are very pleased to have Imegen as a partner in the distribution of MammaPrint and BluePrint because of their knowledge in the area of oncological genomics and experience in the Spanish market," Agendia CEO Mark Straley said in a statement. "Together, we will bring our testing expertise to the nearly 25,000 women annually diagnosed with breast cancer on the Iberian Peninsula."